Regulatory information: adjusted fees for pharmacovigilance applications to EMA from 12/02/2018
Pharmacovigilance fees increase by 1.4%
Pharmacovigilance fees payable to the European Medicines Agency (EMA) by applicants and marketing authorisation holders increase by 1.4% as of 12 February 2018, to reflect inflation rate adjustments of 0.2% for 2015 and 1.2% for 2016.
All applications received by or having a data lock point (DLP) of 11 February will be charged the current fee and reduction rates. Applications received or having a DLP after that date will be charged the adjusted rates.
Further details of the new fee levels are available in Commission Delegated Regulation (EU) 2018/92 amending Regulation (EU) No 658/2014 and the explanatory note on fees.
Latest News from
Change of EUIPO bank account19/02/2018 16:15:00
As from 17 February 2018, one of the two bank accounts used by EUIPO to which users may transfer fees, current account replenishments and charges will change.
Lessons learned from austerity make a change of policy mandatory19/02/2018 15:26:00
The EESC presents measures to avoid the severity of austerity in the future and to mitigate the negative effects of previous crisis management
Mergers: Commission opens in-depth investigation into proposed merger between Praxair and Linde19/02/2018 14:15:00
The EC has opened an in-depth investigation to assess the proposed merger between Praxair and Linde under the EU Merger Regulation. The EC is concerned that the merger may reduce competition in the supply of several crucial gases, like oxygen & helium.
European Defence Fund delivers new pan-European research projects19/02/2018 13:10:00
The European Defence Fund continues to deliver with another set of EU-funded defence research projects. The Fund, launched by President Juncker in June 2017, is a catalyst for the creation of a strong EU defence industry. It boosts defence capabilities and builds new partnerships across borders.